Gilead Remdesivir Trials Boosts Risk Appetite

There are no proven treatments or vaccines for the novel coronavirus which has sickened more than two million people world-wide and killed nearly 150,000 people, but remdesivir is considered a front-runner in the race to develop a treatment for COVID-19 infections that works. Though the findings reported by Stat are promising, they are not based…

Weekly State of the Market: 4/16/2020

Welcome to this week’s State of the Markets with Wayne Nelson and Seth Golden. Please click the following link to review the SOTM video. The password for the SOTM is: B9+09uk! (Must use password) We have achieved the turning point in the COVID-19 saga as the peak of the epidemic curve has been expressed this past week and governments are considering…

Will fiscal policy work quickly enough?

WRITTEN BY VICKY REDWOOD of Capital Economics There is no doubting that governments have generally pulled out all the stops in announcing big fiscal stimulus programmes. But announcing them is one thing; quickly getting the money to where it is needed is quite another. There is a risk that logistical problems prevent fiscal policy from…

Weekly State of the Market: 4/9/2020

Welcome to this week’s State of the Markets with Wayne Nelson and Seth Golden. Please click the following link to review the SOTM video. We are achieving the turning point in the COVID-19 saga as the peak of the epidemic curve has been expressed this past week. Coincidentally, the markets’ relief rally compounded this week with key levels achieved as the…